Klinik und Differenzialdiagnose der thrombotischen Mikroangiopathie

Zurück zum Zitat Gasser C, Gautier E, Steck A, Siebemann RE, Oechslin R (1955) Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia. Schweiz Med Wochenschr 85:905–909PubMed Gasser C, Gautier E, Steck A, Siebemann RE, Oechslin R (1955) Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia. Schweiz Med Wochenschr 85:905–909PubMed

Zurück zum Zitat Moschcowitz E (1924) Hyaline thrombosis of the terminal arterioles and capillaries. A hitherto undescribed disease. Proceedings of the New York Pathological Society 24:21–24 Moschcowitz E (1924) Hyaline thrombosis of the terminal arterioles and capillaries. A hitherto undescribed disease. Proceedings of the New York Pathological Society 24:21–24

Zurück zum Zitat Moake JL (2002) Thrombotic microangiopathies. N Engl J Med 347:589–600CrossRefPubMed Moake JL (2002) Thrombotic microangiopathies. N Engl J Med 347:589–600CrossRefPubMed

Zurück zum Zitat George JN (2010) How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 116:4060–4069CrossRefPubMed George JN (2010) How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 116:4060–4069CrossRefPubMed

Zurück zum Zitat Ståhl AL, Sartz L, Karpman D (2011) Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 117:5503–5513CrossRefPubMed Ståhl AL, Sartz L, Karpman D (2011) Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 117:5503–5513CrossRefPubMed

Zurück zum Zitat Moake J (2009) Thrombotic microangiopathies: multimers, metalloprotease, and beyond. Clin Transl Sci 2:366–373CrossRefPubMedPubMedCentral Moake J (2009) Thrombotic microangiopathies: multimers, metalloprotease, and beyond. Clin Transl Sci 2:366–373CrossRefPubMedPubMedCentral

Zurück zum Zitat Conway EM (2015) HUS and the case for complement. Blood 126:2085–2090CrossRefPubMed Conway EM (2015) HUS and the case for complement. Blood 126:2085–2090CrossRefPubMed

Zurück zum Zitat Menne J, Kielstein JT, Wenzel U, Stahl RA (2012) Treatment of typical hemolytic-uremic syndrome. Knowledge gained from analyses of the 2011 E. coli outbreak. Internist 53:1420–1430CrossRef Menne J, Kielstein JT, Wenzel U, Stahl RA (2012) Treatment of typical hemolytic-uremic syndrome. Knowledge gained from analyses of the 2011 E. coli outbreak. Internist 53:1420–1430CrossRef

Zurück zum Zitat Boyce TG, Swerdlow DL, Griffin PM (1995) Escherichia coli O157:H7 and the hemolytic-uremic syndrome. N Engl J Med 333:364–368CrossRefPubMed Boyce TG, Swerdlow DL, Griffin PM (1995) Escherichia coli O157:H7 and the hemolytic-uremic syndrome. N Engl J Med 333:364–368CrossRefPubMed

Zurück zum Zitat Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5:1844–1859CrossRefPubMedPubMedCentral Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5:1844–1859CrossRefPubMedPubMedCentral

Zurück zum Zitat Riedl M, Fakhouri F, Le Quintrec M, Noone DG, Jungraithmayr TC, Fremeaux-Bacchi V, Licht C (2014) Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost 40:444–4464CrossRefPubMed Riedl M, Fakhouri F, Le Quintrec M, Noone DG, Jungraithmayr TC, Fremeaux-Bacchi V, Licht C (2014) Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost 40:444–4464CrossRefPubMed

Zurück zum Zitat Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa M, Grinyó JM, Praga M, Torra R, Vilalta R, Rodríguez de Córdoba S (2013) An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 33:27–45PubMed Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa M, Grinyó JM, Praga M, Torra R, Vilalta R, Rodríguez de Córdoba S (2013) An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 33:27–45PubMed

Zurück zum Zitat Quaggin SE (2013) DGKE and atypical HUS. Nat Genet 45:475–476CrossRefPubMed Quaggin SE (2013) DGKE and atypical HUS. Nat Genet 45:475–476CrossRefPubMed

Zurück zum Zitat Sallée M, Ismail K, Fakhouri F, Vacher-Coponat H, Moussi-Francés J, Frémaux-Bacchi V, Burtey S (2013) Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome. BMC Nephrol 14:3CrossRefPubMedPubMedCentral Sallée M, Ismail K, Fakhouri F, Vacher-Coponat H, Moussi-Francés J, Frémaux-Bacchi V, Burtey S (2013) Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome. BMC Nephrol 14:3CrossRefPubMedPubMedCentral

Zurück zum Zitat Nguyen TC, Carcillo JA (2006) Bench-to-bedside review: thrombocytopenia-associated multiple organ failure – a newly appreciated syndrome in the critically ill. Crit Care 10:235CrossRefPubMedPubMedCentral Nguyen TC, Carcillo JA (2006) Bench-to-bedside review: thrombocytopenia-associated multiple organ failure – a newly appreciated syndrome in the critically ill. Crit Care 10:235CrossRefPubMedPubMedCentral

Zurück zum Zitat Levi M, Ten Cate H (1999) Disseminated intravascular coagulation. N Engl J Med 341:586–592CrossRefPubMed Levi M, Ten Cate H (1999) Disseminated intravascular coagulation. N Engl J Med 341:586–592CrossRefPubMed

Zurück zum Zitat Lesesve JF, Martin M, Banasiak C, André-Kerneïs E, Bardet V, Lusina D, Kharbach A, Geneviève F, Lecompte T (2014) Schistocytes in disseminated intravascular coagulation. Int J Lab Hematol 36:439–443CrossRefPubMed Lesesve JF, Martin M, Banasiak C, André-Kerneïs E, Bardet V, Lusina D, Kharbach A, Geneviève F, Lecompte T (2014) Schistocytes in disseminated intravascular coagulation. Int J Lab Hematol 36:439–443CrossRefPubMed

Zurück zum Zitat Park YA, Waldrum MR, Marques MB (2010) Platelet count and prothrombin time help distinguish thrombotic thrombocytopenic purpura-hemolytic uremic syndrome from disseminated intravascular coagulation in adults. Am J Clin Pathol 133:460–465CrossRefPubMed Park YA, Waldrum MR, Marques MB (2010) Platelet count and prothrombin time help distinguish thrombotic thrombocytopenic purpura-hemolytic uremic syndrome from disseminated intravascular coagulation in adults. Am J Clin Pathol 133:460–465CrossRefPubMed

Zurück zum Zitat https://c.ymcdn.com/sites/www.isth.org/resource/group/1188b45f-809f-4e2d-b3ef-c6836c51440b/official_communications/definitionofdic.pdf. Zugegriffen: 15. Mai 2016 https://​c.​ymcdn.​com/​sites/​www.​isth.​org/​resource/​group/​1188b45f-809f-4e2d-b3ef-c6836c51440b/​official_​communications/​definitionofdic.​pdf. Zugegriffen: 15. Mai 2016

Zurück zum Zitat Som S, Deford CC, Kaiser ML, Terrell DR, Kremer Hovinga JA, Lämmle B, George JN, Vesely SK (2012) Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. Transfusion 52:2525–2532CrossRefPubMedPubMedCentral Som S, Deford CC, Kaiser ML, Terrell DR, Kremer Hovinga JA, Lämmle B, George JN, Vesely SK (2012) Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. Transfusion 52:2525–2532CrossRefPubMedPubMedCentral

Zurück zum Zitat Sayani FA, Abrams CS (2015) How I treat refractory thrombotic thrombocytopenic purpura. Blood 125:3860–3867CrossRefPubMedPubMedCentral Sayani FA, Abrams CS (2015) How I treat refractory thrombotic thrombocytopenic purpura. Blood 125:3860–3867CrossRefPubMedPubMedCentral

Zurück zum Zitat Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D, TITAN Investigators (2016) Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 374:511–522CrossRefPubMed Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D, TITAN Investigators (2016) Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 374:511–522CrossRefPubMed

Zurück zum Zitat Wong CS, Mooney JC, Brandt JR, Staples AO, Jelacic S, Boster DR, Watkins SL, Tarr PI (2012) Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis 55:33–41CrossRefPubMedPubMedCentral Wong CS, Mooney JC, Brandt JR, Staples AO, Jelacic S, Boster DR, Watkins SL, Tarr PI (2012) Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis 55:33–41CrossRefPubMedPubMedCentral

Zurück zum Zitat Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, Bremer JP, Brunkhorst R, Busch V, Dengler R, Deuschl G, Fellermann K, Fickenscher H, Gerigk C, Goettsche A, Greeve J, Hafer C, Hagenmüller F, Haller H, Herget-Rosenthal S, Hertenstein B, Hofmann C, Lang M, Kielstein JT, Klostermeier UC, Knobloch J, Kuehbacher M, Kunzendorf U, Lehnert H, Manns MP, Menne TF, Meyer TN, Michael C, Münte T, Neumann-Grutzeck C, Nuernberger J, Pavenstaedt H, Ramazan L, Renders L, Repenthin J, Ries W, Rohr A, Rump LC, Samuelsson O, Sayk F, Schmidt BM, Schnatter S, Schöcklmann H, Schreiber S, von Seydewitz CU, Steinhoff J, Stracke S, Suerbaum S, van de Loo A, Vischedyk M, Weissenborn K, Wellhöner P, Wiesner M, Zeissig S, Büning J, Schiffer M, Kuehbacher T, EHEC-HUS consortium (2012) Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 345:e4565CrossRefPubMedPubMedCentral Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, Bremer JP, Brunkhorst R, Busch V, Dengler R, Deuschl G, Fellermann K, Fickenscher H, Gerigk C, Goettsche A, Greeve J, Hafer C, Hagenmüller F, Haller H, Herget-Rosenthal S, Hertenstein B, Hofmann C, Lang M, Kielstein JT, Klostermeier UC, Knobloch J, Kuehbacher M, Kunzendorf U, Lehnert H, Manns MP, Menne TF, Meyer TN, Michael C, Münte T, Neumann-Grutzeck C, Nuernberger J, Pavenstaedt H, Ramazan L, Renders L, Repenthin J, Ries W, Rohr A, Rump LC, Samuelsson O, Sayk F, Schmidt BM, Schnatter S, Schöcklmann H, Schreiber S, von Seydewitz CU, Steinhoff J, Stracke S, Suerbaum S, van de Loo A, Vischedyk M, Weissenborn K, Wellhöner P, Wiesner M, Zeissig S, Büning J, Schiffer M, Kuehbacher T, EHEC-HUS consortium (2012) Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 345:e4565CrossRefPubMedPubMedCentral

Zurück zum Zitat Nitschke M, Sayk F, Härtel C, Roseland RT, Hauswaldt S, Steinhoff J, Fellermann K, Derad I, Wellhöner P, Büning J, Tiemer B, Katalinic A, Rupp J, Lehnert H, Solbach W, Knobloch JK (2012) Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4. JAMA 307:1046–1052CrossRefPubMed Nitschke M, Sayk F, Härtel C, Roseland RT, Hauswaldt S, Steinhoff J, Fellermann K, Derad I, Wellhöner P, Büning J, Tiemer B, Katalinic A, Rupp J, Lehnert H, Solbach W, Knobloch JK (2012) Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4. JAMA 307:1046–1052CrossRefPubMed

Zurück zum Zitat Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G, International Registry of Recurrent and Familial HUS/TTP (2006) Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108:1267–1279CrossRefPubMedPubMedCentral Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G, International Registry of Recurrent and Familial HUS/TTP (2006) Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108:1267–1279CrossRefPubMedPubMedCentral

Zurück zum Zitat Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169–2181CrossRefPubMed Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169–2181CrossRefPubMed

Zurück zum Zitat Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C (2015) Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2‑year extensions of phase 2 studies. Kidney Int 87(1061):1073 Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C (2015) Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2‑year extensions of phase 2 studies. Kidney Int 87(1061):1073